A new way to treat narcolepsy
The US Food and Drug Administration has approved Oveporexton, a first-in-class drug for narcolepsy. The treatment works by restoring orexin signaling in the brain, the system that helps regulate wakefulness and sleep. Most people with narcolepsy have lost the neurons that produce orexin.
Older treatments, mostly stimulants, mask the symptoms of excessive daytime sleepiness. Oveporexton takes a different path. It targets the underlying loss of orexin signaling, an approach researchers have pursued for two decades.
The approval is a milestone for the field. Narcolepsy affects roughly three million people worldwide, and many patients say existing drugs leave them tired and foggy. A therapy aimed at the root cause offers a new kind of hope.
What the trials showed
In clinical trials, patients taking the drug reported fewer daytime sleep attacks and more stable nighttime sleep. Some also saw improvement in cataplexy, the sudden muscle weakness triggered by emotion that affects many people with narcolepsy. The drug is taken once a day.
Approval is limited to people aged 50 and older, the FDA said. The agency asked for more data on younger patients before widening the label. Common side effects include headache, nausea and changes in sleep patterns.
Researchers noted that the drug restores orexin signaling rather than simply boosting alertness. That difference matters, they said, because it treats the disease process itself. Longer studies will show whether the effect holds up over years of use.
Why this matters
Narcolepsy can disrupt work, school and relationships, and patients often cycle through treatments with limited success. Many go undiagnosed for years because symptoms are mistaken for laziness or depression.
Oveporexton is the first approved therapy to restore orexin signaling rather than merely manage symptoms. Researchers said the approval validates a mechanism that could one day apply to other sleep and neurological disorders.
Doctors caution that long-term safety is not yet known, and the drug's cost may limit access. Still, patient groups welcomed the news. For older adults with narcolepsy, a once-daily pill that targets the cause is a step they have waited years to see.